NEOGENOMICS INC Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Neogenomics Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2014 to Q3 2024.
  • Neogenomics Inc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $8.47M, a 18% increase year-over-year.
  • Neogenomics Inc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $32M, a 43.4% increase year-over-year.
  • Neogenomics Inc annual Share-based Payment Arrangement, Expense for 2023 was $24.6M, a 0.41% decline from 2022.
  • Neogenomics Inc annual Share-based Payment Arrangement, Expense for 2022 was $24.7M, a 9.78% increase from 2021.
  • Neogenomics Inc annual Share-based Payment Arrangement, Expense for 2021 was $22.5M.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $32M $8.47M +$1.29M +18% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $30.8M $8.84M +$3.14M +55% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-30
Q1 2024 $27.6M $7.77M +$3.02M +63.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-30
Q4 2023 $24.6M $6.96M +$2.26M +48% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $22.3M $7.18M +$2.88M +67% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $19.5M $5.71M +$2.11M +58.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-30
Q1 2023 $17.4M $4.76M -$7.34M -60.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-30
Q4 2022 $24.7M $4.7M -$5.4M -53.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $30.1M $4.3M -$900K -17.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $31M $3.6M -$900K -20% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $31.9M $12.1M +$9.4M +348% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $22.5M $10.1M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $5.2M +$2.5M +92.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $4.5M +$1.9M +73.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $2.7M +$500K +22.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q3 2020 $2.7M -$600K -18.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $2.6M +$300K +13% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $2.2M +$100K +4.76% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q3 2019 $3.3M +$2.2M +200% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-29
Q2 2019 $2.3M Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-31
Q1 2019 $2.1M +$500K +31.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-29
Q3 2018 $1.1M -$1.7M -60.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q1 2018 $1.6M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q3 2017 $2.8M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q3 2015 $828K +$508K +159% Jul 1, 2015 Sep 30, 2015 10-Q 2015-11-06
Q2 2015 $508K +$351K +224% Apr 1, 2015 Jun 30, 2015 10-Q 2015-07-31
Q1 2015 $342K +$253K +284% Jan 1, 2015 Mar 31, 2015 10-Q 2015-05-11
Q3 2014 $320K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 $157K Apr 1, 2014 Jun 30, 2014 10-Q 2015-07-31
Q1 2014 $89K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.